KLK-HM102-100μg / 询价
KLK-HM102-500μg / 询价
KLK-HM102-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Human Kallikrein 2/KLK2 Protein (active form)
Recombinant Human Kallikrein 2/KLK2 Protein (active form) is expressed from HEK293 with His tag at the C-terminus.It contains Ile25-Pro261 [Accession | P20151-1].
The protein has a predicted MW of 27.4 kDa. Due to glycosylation, the protein migrates to 27-35 kDa based on Bis-Tris PAGE result.
> 90% as determined by Bis-Tris PAGE
Less than 0.1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in 20mM Tris, 150mM NaCl, 8% trehalose, 0.05% Brij-35, 5mM Benzamidine (pH 8.0).
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Kallikrein-related peptidase 2 (KLK2) is a serine protease exhibiting antiangiogenic properties through proteolytic activity. KLK2 is overexpressed in prostate cancer and plays a pivotal role in cancer progression, establishing it as a potential therapeutic target.
KLK2; Kallikrein 2; hGK-1; hK2; KLK2A2
Jairajpuri DS, Hussain A, Alajmi MF, Mohammad T, Shamsi A, Hassan MI. Structure-based identification of bioactive phytochemicals targeting kallikrein-related peptidase 2 for prostate cancer therapy. Front Chem. 2025 Mar 26;13:1553987. doi: 10.3389/fchem.2025.1553987. PMID: 40207180; PMCID: PMC11979280.
